Severe arthritis and tenosynovitis caused by immune checkpoint blockade therapy with pembrolizumab (anti-PD-1 antibody)
Identifieur interne : 000434 ( Main/Exploration ); précédent : 000433; suivant : 000435Severe arthritis and tenosynovitis caused by immune checkpoint blockade therapy with pembrolizumab (anti-PD-1 antibody)
Auteurs : Aprajita Jagpal ; Gagandeep Choudhary ; Jad Chokr [Liban]Source :
- Proceedings (Baylor University. Medical Center) [ 0899-8280 ] ; 2019.
Abstract
Pembrolizumab, a monoclonal antibody against the immune checkpoint receptor–programmed cell death protein 1, has proven clinical efficacy in melanoma and other solid tumors. It increases the body’s immune response against the tumor cells. However, because of an uninhibited immune system, immune-mediated adverse effects can arise. Though most adverse effects from pembrolizumab involve the gastrointestinal tract, skin, and endocrine system, rheumatologic manifestations are not very well defined. We describe two cases of severe inflammatory arthritis and tenosynovitis, which are rare adverse effects of pembrolizumab. Increased awareness of this manifestation is imperative to establish the diagnosis and initiate timely treatment.
Url:
DOI: 10.1080/08998280.2019.1588654
PubMed: 31384207
PubMed Central: 6650205
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 000271
- to stream Pmc, to step Curation: 000271
- to stream Pmc, to step Checkpoint: 000391
- to stream Ncbi, to step Merge: 000887
- to stream Ncbi, to step Curation: 000887
- to stream Ncbi, to step Checkpoint: 000887
- to stream Main, to step Merge: 000434
- to stream Main, to step Curation: 000434
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Severe arthritis and tenosynovitis caused by immune checkpoint blockade therapy with pembrolizumab (anti-PD-1 antibody)</title><author><name sortKey="Jagpal, Aprajita" sort="Jagpal, Aprajita" uniqKey="Jagpal A" first="Aprajita" last="Jagpal">Aprajita Jagpal</name><affiliation><nlm:aff id="AF0001"><institution>Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham</institution>BirminghamAlabama</nlm:aff></affiliation></author><author><name sortKey="Choudhary, Gagandeep" sort="Choudhary, Gagandeep" uniqKey="Choudhary G" first="Gagandeep" last="Choudhary">Gagandeep Choudhary</name><affiliation><nlm:aff id="AF0002"><institution>Department of Radiology, University of Alabama at Birmingham</institution>BirminghamAlabama</nlm:aff></affiliation></author><author><name sortKey="Chokr, Jad" sort="Chokr, Jad" uniqKey="Chokr J" first="Jad" last="Chokr">Jad Chokr</name><affiliation wicri:level="1"><nlm:aff id="AF0003"><institution>Department of Radiology, Clemenceau Medical Center, affiliated with Johns Hopkins</institution>Beirut<country>Lebanon</country></nlm:aff><country xml:lang="fr">Liban</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">31384207</idno><idno type="pmc">6650205</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6650205</idno><idno type="RBID">PMC:6650205</idno><idno type="doi">10.1080/08998280.2019.1588654</idno><date when="2019">2019</date><idno type="wicri:Area/Pmc/Corpus">000271</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000271</idno><idno type="wicri:Area/Pmc/Curation">000271</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000271</idno><idno type="wicri:Area/Pmc/Checkpoint">000391</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000391</idno><idno type="wicri:Area/Ncbi/Merge">000887</idno><idno type="wicri:Area/Ncbi/Curation">000887</idno><idno type="wicri:Area/Ncbi/Checkpoint">000887</idno><idno type="wicri:doubleKey">0899-8280:2019:Jagpal A:severe:arthritis:and</idno><idno type="wicri:Area/Main/Merge">000434</idno><idno type="wicri:Area/Main/Curation">000434</idno><idno type="wicri:Area/Main/Exploration">000434</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Severe arthritis and tenosynovitis caused by immune checkpoint blockade therapy with pembrolizumab (anti-PD-1 antibody)</title><author><name sortKey="Jagpal, Aprajita" sort="Jagpal, Aprajita" uniqKey="Jagpal A" first="Aprajita" last="Jagpal">Aprajita Jagpal</name><affiliation><nlm:aff id="AF0001"><institution>Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham</institution>BirminghamAlabama</nlm:aff></affiliation></author><author><name sortKey="Choudhary, Gagandeep" sort="Choudhary, Gagandeep" uniqKey="Choudhary G" first="Gagandeep" last="Choudhary">Gagandeep Choudhary</name><affiliation><nlm:aff id="AF0002"><institution>Department of Radiology, University of Alabama at Birmingham</institution>BirminghamAlabama</nlm:aff></affiliation></author><author><name sortKey="Chokr, Jad" sort="Chokr, Jad" uniqKey="Chokr J" first="Jad" last="Chokr">Jad Chokr</name><affiliation wicri:level="1"><nlm:aff id="AF0003"><institution>Department of Radiology, Clemenceau Medical Center, affiliated with Johns Hopkins</institution>Beirut<country>Lebanon</country></nlm:aff><country xml:lang="fr">Liban</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author></analytic><series><title level="j">Proceedings (Baylor University. Medical Center)</title><idno type="ISSN">0899-8280</idno><idno type="eISSN">1525-3252</idno><imprint><date when="2019">2019</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><title>Abstract</title><p>Pembrolizumab, a monoclonal antibody against the immune checkpoint receptor–programmed cell death protein 1, has proven clinical efficacy in melanoma and other solid tumors. It increases the body’s immune response against the tumor cells. However, because of an uninhibited immune system, immune-mediated adverse effects can arise. Though most adverse effects from pembrolizumab involve the gastrointestinal tract, skin, and endocrine system, rheumatologic manifestations are not very well defined. We describe two cases of severe inflammatory arthritis and tenosynovitis, which are rare adverse effects of pembrolizumab. Increased awareness of this manifestation is imperative to establish the diagnosis and initiate timely treatment.</p></div></front></TEI><affiliations><list><country><li>Liban</li></country></list><tree><noCountry><name sortKey="Choudhary, Gagandeep" sort="Choudhary, Gagandeep" uniqKey="Choudhary G" first="Gagandeep" last="Choudhary">Gagandeep Choudhary</name><name sortKey="Jagpal, Aprajita" sort="Jagpal, Aprajita" uniqKey="Jagpal A" first="Aprajita" last="Jagpal">Aprajita Jagpal</name></noCountry><country name="Liban"><noRegion><name sortKey="Chokr, Jad" sort="Chokr, Jad" uniqKey="Chokr J" first="Jad" last="Chokr">Jad Chokr</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000434 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000434 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= PMC:6650205
|texte= Severe arthritis and tenosynovitis caused by immune checkpoint blockade therapy with pembrolizumab (anti-PD-1 antibody)
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:31384207" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a ChloroquineV1
| This area was generated with Dilib version V0.6.33. |  |